SCHEMBL853544

SCHEMBL853544

NCCN1C(=O)CNC1=O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.50
GSK3A P49840 1/20 0.46
GSK3B P49841 1/20 0.46
ABL1 P00519 1/20 0.35
LMNA P02545 1/20 0.35
RIN1 Q13671 1/20 0.35
ALDH1A1 P00352 3/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
QPCT Q16769 1/20 0.33
GAA P10253 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HEXA P06865 1/20 0.32
HEXB P07686 1/20 0.32
KDM4E B2RXH2 1/20 0.32
PKM P14618 1/20 0.32
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2980753 0.98 TSHR (0.48) TSHRGSK3AGSK3BABL1LMNA
SCHEMBL9755587 0.87 TSHR (0.47) TSHRGSK3AGSK3BABL1LMNA
SCHEMBL31420563 0.82 TSHR (0.43) TSHRGSK3AGSK3BABL1LMNA
SCHEMBL11483737 0.81
SCHEMBL10979078 0.77 TSHR (0.50) TSHRGSK3AGSK3BABL1LMNA
SCHEMBL10963438 0.77 TSHR (0.50) TSHRGSK3AGSK3BABL1LMNA
SCHEMBL1969772 0.77 TSHR (0.55) TSHRGSK3AGSK3BABL1LMNA
SCHEMBL839846 0.77 TSHR (0.50) TSHRGSK3AGSK3BABL1LMNA
SCHEMBL7330397 0.77 TSHR (0.50) TSHRGSK3AGSK3BABL1LMNA
SCHEMBL7453981 0.74 TSHR (0.47) TSHRGSK3AGSK3BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 US disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 WO disclosed
EP-4262819-A1 NANOMATERIALS COMPRISING ESTER-LINKED ACETALS Beam Therapeutics Inc. (US) 2023-10-25 EP disclosed
US-20230331657-A1 NANOMATERIALS COMPRISING ESTER-LINKED ACETALS BEAM THERAPEUTICS INC. 2023-10-19 US disclosed
CN-116887841-A Nanomaterials comprising ester-linked acetals 比姆医疗股份有限公司 2023-10-13 CN disclosed
EP-4249492-A1 NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND ANTIBIOTIC COMPOSITION COMPRISING SAME A&J Science Co.,Ltd. (KR) 2023-09-27 EP disclosed
WO-2022140252-A1 NANOMATERIALS COMPRISING ESTER-LINKED ACETALS BEAM THERAPEUTICS INC. (US) 2022-06-30 WO disclosed
CN-102827082-B Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO CO LTD 2015-01-07 CN disclosed
US-8901315-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-02 US disclosed
US-20140073799-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-03-13 US disclosed
EP-1775298-B1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY DAIICHI SANKYO CO LTD (JP) 2013-03-20 EP disclosed
EP-2433943-A1 Thienopyrazole derivatives having PDE7 inhibitory activity Daiichi Sankyo Company, Limited (JP) 2012-03-28 EP disclosed
US-20110166343-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-07-07 US disclosed
US-7932250-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-04-26 US disclosed
US-20090131413-A1 Thienopyrazole Derivative Having PDE7 Inhibitory Activity ASUBIO PHARMA CO., LTD. (JP) 2009-05-21 US disclosed
EP-1775298-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY Daiichi Asubio Pharma Co., Ltd. (JP) 2007-04-18 EP disclosed
US-4772693-A 2-oxo-1-((Substituted sulfonyl)amino)-carbonyl)azetidines E. R. SQUIBB & SONS, INC. (US) 1988-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073799-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY PDE7A, PDE7B, PDE3B TSHR 389/4885GSK3A 2995/4885GSK3B 2538/4885
US-20110166343-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY PDE7A, PDE7B, PDE3B TSHR 389/4885GSK3A 2995/4885GSK3B 2538/4885
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS TSHR 3973/4885GSK3A 536/4885GSK3B 566/4885
US-20230331657-A1 NANOMATERIALS COMPRISING ESTER-LINKED ACETALS LIPA, SGMS1, SGMS2 TSHR 4628/4885GSK3A 2065/4885GSK3B 2191/4885
US-20090131413-A1 Thienopyrazole Derivative Having PDE7 Inhibitory Activity PDE7A, PDE7B, PDE3B TSHR 389/4885GSK3A 2995/4885GSK3B 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.